India Exchange Filings

Kwality Pharmaceuticals Q2 FY27 Earnings and Board Meeting Highlights

Kwality Pharmaceuticals Ltd reports Q2 FY27 consolidated revenue of ₹181.22 crore, up 63.2% YoY, and PAT of ₹29.03 crore.

  • EBITDA margin was 27.5%; PAT rose 105.6% YoY and 13.3% QoQ. No exceptional items; limited-review reports were unmodified.
  • FY27 revenue guidance raised to ₹720 crore or more from ₹700 crore.
  • Board approved B S R & Co. LLP as replacement auditor, subject to member approval, following Vijay Mehra & Co.’s resignation.
  • Management discussion cites Q2 PAT of ₹50 crore, differing from consolidated results PAT of ₹29.03 crore.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.